Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US aerospace and defense stocks remain chilly! JPMorgan warns: Military spending outlook darkens, cooling aviation demand, and even positive Q3 results may not reverse the downturn

US aerospace and defense stocks remain chilly! JPMorgan warns: Military spending outlook darkens, cooling aviation demand, and even positive Q3 results may not reverse the downturn

智通财经智通财经2026/10/09 04:01
Show original

According to information from Zhitong Finance APP, JPMorgan believes that aerospace and defense companies are about to face a challenging third-quarter earnings season. The slowing growth of air passenger traffic, uncertainties about the outlook for U.S. military spending, and persistent supply chain constraints are all weighing on investor sentiment.

According to Smart Finance APP, JPMorgan believes that aerospace and defense companies are about to face a challenging third-quarter earnings season—slowing growth in air passenger traffic, uncertainty over the outlook for U.S. military spending, and persistent supply chain constraints are all putting pressure on investor sentiment.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%